draft
More than 150 hepatologists meet in Santander for 15th edition Hepatology multidisciplinary open classroom, A two-day conference organized by Gilead Sciences, in which Hepatitis C virus He has been one of the protagonists of talks and meetings, as well as the assertions of experts pointing out how close Spain is to ending the virus.
“We have little capacity left to eliminate hepatitis C virus, but we must continue to move forward to achieve this goal, complete the work we have left and make Spain one of the first countries in the world to achieve this goal”has claimed Dr. Javier CrespoRecalls a specialist at the Marqués de Valdecilla University Hospital in Santander and co-coordinator of Aula Abierta “That It is necessary to do the job wellwill become a model for the whole world.”.
Dr. Javier Crespo believes that Spain “needs to do a good job” on the hepatitis C virus
Spain is still youNot one of the countries best equipped to eliminate hepatitis C virus (HCV), according to the 2030 targets set by the World Health Organization (WHO).Continue to promote viral hepatitis elimination strategies and continue “Committed to innovation”is a key aspect in achieving your goals.
More than 164,502 hepatitis C patients have been treated in Spain, with a cure rate of approximately 95%.But liver disease experts say more than 76,000 people still have active hepatitis C virus infections, including 22,500 people have not been diagnosed.
More than 164,502 hepatitis C patients have been treated in Spain, with a cure rate of approximately 95%.But liver disease experts point out that more than 76,000 people still have active infections
Marta Velázquez, Senior Business Unit Director Gilead Sciences liver disease research highlights, “Gilead’s commitment and efforts not only target Develop innovative medicines or train health professionals, but implements projects and scholarships for scientific associations, health institutions and non-governmental organizations that allow us to achieve elimination in our country. “For the past 20 years, we have been on the front lines of transforming care for patients with hepatitis B and are committed to tackling hepatitis D”.
Hepatitis D is one of the topics in this edition “Because of important advances in its diagnosis and treatment”points out that Dr. José Luis Calleja, from the Porta Hierro University Hospital in Madrid and co-coordinator of this meeting. Pathologies such as drug-induced liver injury (DILI) or Wilson’s disease, metabolic hepatic steatosis (MASLD, formerly known as non-alcoholic fatty liver disease), alcohol-associated hepatic steatosis (ALD), and steatosis have also been reviewed. Metabolic Dysfunction and Alcohol (MetALD).
Dr. José Luis Calleja: “We want young researchers to tell us what they are doing, what unanswered aspects they see in their research and what we can do together”
The city of Santander also hosts Lega-C 3rd EditionAt this meeting, the research status and challenges in the fields of ALD, MASLD, and viral hepatitis B and D were debated and shared through working groups.In this field, we also seek “It was also discovered what unmet needs, precisely, should be the subject of investigation”Dr. Calleja noted.
“Lega C is designed for young researchers. We work with them and want them to tell us what they are doing, what unanswered aspects they see in their research and what we can do together. Committed to what they do things, what they want to do and how we can do it together. Help them organize those thoughts. Something crucial for them to continue training.”” added Dr. Crespo.